VolitionRX (NYSEAMERICAN:VNRX) has been given a $10.00 target price by research analysts at HC Wainwright in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 244.83% from the stock’s previous close.
VolitionRX (VNRX) traded down $0.13 during mid-day trading on Tuesday, reaching $2.90. The company had a trading volume of 80,277 shares, compared to its average volume of 126,026. The firm has a market cap of $76.90, a P/E ratio of -5.58 and a beta of -0.97. VolitionRX has a fifty-two week low of $2.08 and a fifty-two week high of $4.71.
VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, November 9th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01).
VolitionRX Company Profile
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.